<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39348348</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>9</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals: Case studies in the Indo-Pacific.</ArticleTitle><Pagination><StartPage>e0294091</StartPage><MedlinePgn>e0294091</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0294091</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0294091</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Decision-makers in middle-income countries need evidence on the cost-effectiveness of COVID-19 booster doses and oral antivirals to appropriately prioritise these healthcare interventions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used a dynamic transmission model to assess the cost-effectiveness of COVID-19 booster doses and oral antivirals in Fiji, Indonesia, Papua New Guinea, and Timor-Leste. We conducted cost-effectiveness analysis from both healthcare and societal perspectives using data collated from publicly available sources. We developed an interactive R Shiny which allows the user to vary key model assumptions, such as the choice of discounting rate, and view how these assumptions affect model results.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Booster doses were cost saving and therefore cost-effective in all four middle-income settings from both healthcare and societal perspectives using 3% discounting. Providing oral antivirals was cost-effective from a healthcare perspective if procured at a low generic price (US$25) or middle-income reference price (US$250); however, their cost-effectiveness was strongly influenced by rates of wastage or misuse, and the ongoing costs of care for patients hospitalised with COVID-19. The cost or wastage of rapid antigen tests did not appear strongly influential over the cost-effectiveness of oral antivirals in any of the four study settings.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results support that COVID-19 booster programs are cost-effective in middle-income settings. Oral antivirals demonstrate the potential to be cost-effective if procured at or below a middle-income reference price of US$250 per schedule. Further research should quantify the rates of wastage or misuse of oral COVID-19 antivirals in middle-income settings.</AbstractText><CopyrightInformation>Copyright: © 2024 Bilgin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bilgin</LastName><ForeName>Gizem Mayis</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0001-6824-4376</Identifier><AffiliationInfo><Affiliation>National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munira</LastName><ForeName>Syarifah Liza</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Faculty of Economics and Business, Universitas Indonesia, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lokuge</LastName><ForeName>Kamalini</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="Y">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007214" MajorTopicYN="N" Type="Geographic">Indonesia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005367" MajorTopicYN="N" Type="Geographic">Fiji</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010219" MajorTopicYN="N" Type="Geographic">Papua New Guinea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094703" MajorTopicYN="N">Cost-Effectiveness Analysis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>22</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>13</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39348348</ArticleId><ArticleId IdType="pmc">PMC11441647</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0294091</ArticleId><ArticleId IdType="pii">PONE-D-23-34679</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al.. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. The Lancet Infectious Diseases. 2021;21(4):e75–e6. doi: 10.1016/S1473-3099(20)30631-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30631-9</ArticleId><ArticleId IdType="pmc">PMC7402646</ArticleId><ArticleId IdType="pubmed">32763195</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–4. doi: 10.1016/S1473-3099(20)30120-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30120-1</ArticleId><ArticleId IdType="pmc">PMC7159018</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO SAGE roadmap on uses of COVID-19 vaccines in the context of Omicron and substantial population immunity: an approach to optimize the global impact of COVID-19 vaccines at a time when Omicron and its sub-lineages are the dominant circulating variants of concern, based on public health goals, evolving epidemiology, and increasing population-level immunity, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, update: 21 January 2022, latest update: 30 March 2023. Geneva: World Health Organization, 2023. Contract No.: WHO/2019-nCoV/Vaccines/SAGE/Prioritization/2023.1.</Citation></Reference><Reference><Citation>Sasanami M, Fujimoto M, Kayano T, Hayashi K, Nishiura H. Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination. Journal of Theoretical Biology. 2023;559:111384. doi: 10.1016/j.jtbi.2022.111384</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtbi.2022.111384</ArticleId><ArticleId IdType="pmc">PMC9749381</ArticleId><ArticleId IdType="pubmed">36528092</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgin GM, Lokuge K, Munira SL, Glass K. Assessing the potential impact of COVID-19 booster doses and oral antivirals: A mathematical modelling study of selected middle-income countries in the Indo-Pacific. Vaccine: X. 2023;15:100386. doi: 10.1016/j.jvacx.2023.100386</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2023.100386</ArticleId><ArticleId IdType="pmc">PMC10506093</ArticleId><ArticleId IdType="pubmed">37727365</ArticleId></ArticleIdList></Reference><Reference><Citation>The World Bank. World Bank Open Data [Cited 06/07/2023]. https://data.worldbank.org/.</Citation></Reference><Reference><Citation>International Monetary Fund. World Economic Outlook Database: April 2023 [Cited 12/04/2023]. https://www.imf.org/en/Publications/WEO/weo-database/2023/April.</Citation></Reference><Reference><Citation>Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for Inflation and Currency Changes Within Health Economic Studies. Value Health. 2019;22(9):1026–32. doi: 10.1016/j.jval.2019.03.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2019.03.021</ArticleId><ArticleId IdType="pubmed">31511179</ArticleId></ArticleIdList></Reference><Reference><Citation>Izadi R, Hatam N, Baberi F, Yousefzadeh S, Jafari A. Economic evaluation of strategies against coronavirus: a systematic review. Health Economics Review. 2023;13(1):18. doi: 10.1186/s13561-023-00430-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13561-023-00430-1</ArticleId><ArticleId IdType="pmc">PMC10024293</ArticleId><ArticleId IdType="pubmed">36933043</ArticleId></ArticleIdList></Reference><Reference><Citation>International Vaccine Access Center, World Health Organization. Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review. 2022.</Citation></Reference><Reference><Citation>Bilgin GM, Lokuge K, Jabbie E, Munira SL, Glass K. COVID-19 vaccination strategies in settings with limited rollout capacity: a mathematical modelling case study in Sierra Leone. BMC Public Health. 2023;23(1):2466. doi: 10.1186/s12889-023-17374-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-023-17374-0</ArticleId><ArticleId IdType="pmc">PMC10712073</ArticleId><ArticleId IdType="pubmed">38082260</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Therapeutics and COVID-19: living guideline, 13 January 2023. Geneva: World Health Organization, 2023. Contract No.: WHO/2019-nCoV/therapeutics/2023.1.</Citation></Reference><Reference><Citation>Robinson LA, Eber MR, Hammitt JK. Valuing COVID-19 Morbidity Risk Reductions. Journal of Benefit-Cost Analysis. 2022;13(2):247–68. doi: 10.1017/bca.2022.11</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/bca.2022.11</ArticleId><ArticleId IdType="pmc">PMC9455599</ArticleId><ArticleId IdType="pubmed">36090595</ArticleId></ArticleIdList></Reference><Reference><Citation>World Population Prospects 2019. 2019 [Cited 26/11/2021]. https://population.un.org/wpp/Download/Standard/Mortality/.</Citation></Reference><Reference><Citation>GAVI. The List of AMC-Eligible Economies 2021 [Cited 15/03/2023]. https://www.gavi.org/gavi-covax-amc.</Citation></Reference><Reference><Citation>United Nation’s Children’s Fund. COVID-19 Market Dashboard 2022 [Cited 15/12/2022]. https://www.unicef.org/supply/covid-19-market-dashboard.</Citation></Reference><Reference><Citation>Sim SY, Watts E, Constenla D, Huang S, Brenzel L, Patenaude BN. Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030. Value Health. 2021;24(1):70–7. doi: 10.1016/j.jval.2020.07.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2020.07.010</ArticleId><ArticleId IdType="pmc">PMC7813215</ArticleId><ArticleId IdType="pubmed">33431156</ArticleId></ArticleIdList></Reference><Reference><Citation>Papua New Guinea National Departmnet of Health. Comprehensive EPI Multi-Year Plan for National Immunization Programme 2016–2020. 2016.</Citation></Reference><Reference><Citation>Ministry of Health. A Comprehensive Multi Year Plan 2016–2020: the national immunization program in Timor-Leste. 2015.</Citation></Reference><Reference><Citation>Kementerian Kesehatan Republik Indonesia. Comprehensive Multi Year Plan National Immunization Program Indonesia, 2020–2024. 2019.</Citation></Reference><Reference><Citation>Mow M, Thean LJ, Parnaby M, Mani J, Rafai E, Sahukhan A, et al.. Costs of mass drug administration for scabies in Fiji. PLOS Neglected Tropical Diseases. 2022;16(2):e0010147. doi: 10.1371/journal.pntd.0010147</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0010147</ArticleId><ArticleId IdType="pmc">PMC8846527</ArticleId><ArticleId IdType="pubmed">35113888</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Immunization dashboard 2023 [Cited 05/05/2023]. https://immunizationdata.who.int/index.html.</Citation></Reference><Reference><Citation>World Health Organization. Seasonal influenza vaccine use in low and middle income countries in the tropics and subtropics: a systematic review. Geneva: World Health Organization, 2015. 9789241565097.</Citation></Reference><Reference><Citation>Lazarus JV, Abdool Karim SS, van Selm L, Doran J, Batista C, Ben Amor Y, et al.. COVID-19 vaccine wastage in the midst of vaccine inequity: causes, types and practical steps. BMJ Global Health. 2022;7(4):e009010. doi: 10.1136/bmjgh-2022-009010</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2022-009010</ArticleId><ArticleId IdType="pmc">PMC9044511</ArticleId><ArticleId IdType="pubmed">35474267</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Monitoring vaccine wastage at country level: guidelines for programme managers. Geneva: World Health Organization; 2005.</Citation></Reference><Reference><Citation>Manas Mishra. U.S. to buy 10 mln courses of Pfizer’s COVID-19 pill for $5.3 bln 2021 [Cited 17/03/2023]. https://www.reuters.com/business/healthcare-pharmaceuticals/us-govt-buy-10-mln-courses-pfizers-covid-19-pill-529-bln-2021-11-18/.</Citation></Reference><Reference><Citation>Malaysian Health Technology Assessment Section. Protease Inhibitors (Paxlovid®)–Oral Treatment for COVID-19 (updated). 2022.</Citation></Reference><Reference><Citation>Press release: CHAI announces agreements with leading generic manufacturers to make affordable COVID-19 treatment available in low- and middle-income countries. 2022 [Cited 17/03/2023]. https://www.clintonhealthaccess.org/news/chai-announces-agreements-with-leading-generic-manufacturers-to-make-affordable-covid-19-treatment-available-in-low-and-middle-income-countries/</Citation></Reference><Reference><Citation>Bhattarai S, Chee H-Y, Japri A, Wiyarta E, Anderson BD. The Epidemiology of Human Respiratory Viruses in Indonesia: A Systematic Review. SSRN Electronic Journal. 2022. doi: 10.2139/ssrn.4205782</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4205782</ArticleId></ArticleIdList></Reference><Reference><Citation>Menkir TF, Donnelly CA. The impact of repeated rapid test strategies on the effectiveness of at-home antiviral treatments for SARS-CoV-2. Nature Communications. 2022;13(1):5283. doi: 10.1038/s41467-022-32640-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32640-2</ArticleId><ArticleId IdType="pmc">PMC9453717</ArticleId><ArticleId IdType="pubmed">36075923</ArticleId></ArticleIdList></Reference><Reference><Citation>United Nation’s Children’s Fund. COVID-19 vaccine price data 2023 [Cited 15/03/2023]. https://www.unicef.org/supply/documents/covid-19-vaccine-price-data.</Citation></Reference><Reference><Citation>COVAX. Costs of delivering COVID-19 vaccine in 92 AMC countries. 2021.</Citation></Reference><Reference><Citation>World Health Organization. Guidelines for estimating costs of introducing new vaccines into the national immunization system. Geneva: World Health Organization; 2002.</Citation></Reference><Reference><Citation>Insitute for Clinical and Economic Review. Special Assessment of Outpatient Treatments for COVID-19:Final Evidence Report and Meeting Summary. 2022.</Citation></Reference><Reference><Citation>Jo Y, Kim SB, Radnaabaatar M, Huh K, Yoo JH, Peck KR, et al.. Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea. Epidemiol Health. 2022;44:e2022034. doi: 10.4178/epih.e2022034</Citation><ArticleIdList><ArticleId IdType="doi">10.4178/epih.e2022034</ArticleId><ArticleId IdType="pmc">PMC9350420</ArticleId><ArticleId IdType="pubmed">35381167</ArticleId></ArticleIdList></Reference><Reference><Citation>Savinkina A, Gonsalves G, Ross JS, Paltiel AD. Determining population-level allocation strategies for COVID-19 treatments in the United States using a quantitative framework, a case study using nirmatrelvir/ritonavir. medRxiv. 2022:2022.08.04.22278431. doi: 10.1101/2022.08.04.22278431</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.04.22278431</ArticleId></ArticleIdList></Reference><Reference><Citation>Albarqouni L, Palagama S, Chai J, Sivananthajothy P, Pathirana T, Bakhit M, et al.. Overuse of medications in low- and middle-income countries: a scoping review. Bulletin of the World Health Organization. 2023;101(1):36–61D. doi: 10.2471/BLT.22.288293</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.22.288293</ArticleId><ArticleId IdType="pmc">PMC9795388</ArticleId><ArticleId IdType="pubmed">36593777</ArticleId></ArticleIdList></Reference><Reference><Citation>United Nation’s Children’s Fund. Rapid Tests 2023 [Cited 17/03/2023]. https://supply.unicef.org/all-materials/covid-diagnostic-test/serological-tests/rapid-tests.html.</Citation></Reference><Reference><Citation>World Health Organization. WHO-CHOICE estimates of cost for inpatient and outpatient health service delivery. 2021.</Citation></Reference><Reference><Citation>Nugraha RR, Pratiwi MA, Al-Faizin RE, Permana AB, Setiawan E, Farianty Y, et al.. Predicting the cost of COVID-19 treatment and its drivers in Indonesia: analysis of claims data of COVID-19 in 2020–2021. Health Economics Review. 2022;12(1):45. doi: 10.1186/s13561-022-00392-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13561-022-00392-w</ArticleId><ArticleId IdType="pmc">PMC9428372</ArticleId><ArticleId IdType="pubmed">36044109</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke N, Johnson S, Bahl A. Boosters reduce in-hospital mortality in patients with COVID-19: An observational cohort analysis. The Lancet Regional Health - Americas. 2022;8:100227. doi: 10.1016/j.lana.2022.100227</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100227</ArticleId><ArticleId IdType="pmc">PMC8926847</ArticleId><ArticleId IdType="pubmed">35313615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SW, Ma D, Davoodian A, Ayutyanont N, Werner B. COVID-19 vaccination decreased COVID-19 hospital length of stay, in-hospital death, and increased home discharge. Preventive Medicine Reports. 2023;32:102152. doi: 10.1016/j.pmedr.2023.102152</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmedr.2023.102152</ArticleId><ArticleId IdType="pmc">PMC9933576</ArticleId><ArticleId IdType="pubmed">36811076</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruni A, Longhini F, Macheda S, Biamonte E, Pasqua P, Neri G, et al.. Characteristics of unvaccinated and vaccinated critically ill COVID-19 patients in calabria region (Italy): A retrospective study. Front Med (Lausanne). 2022;9. doi: 10.3389/fmed.2022.1042411</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1042411</ArticleId><ArticleId IdType="pmc">PMC9729689</ArticleId><ArticleId IdType="pubmed">36507545</ArticleId></ArticleIdList></Reference><Reference><Citation>de Broucker G, Sim SY, Brenzel L, Gross M, Patenaude B, Constenla DO. Cost of Nine Pediatric Infectious Illnesses in Low- and Middle-Income Countries: A Systematic Review of Cost-of-Illness Studies. PharmacoEconomics. 2020;38(10):1071–94. doi: 10.1007/s40273-020-00940-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-020-00940-4</ArticleId><ArticleId IdType="pmc">PMC7578143</ArticleId><ArticleId IdType="pubmed">32748334</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. Geneva: World Health Organization, 2019. Contract No.: WHO/IVB/19.10.</Citation></Reference><Reference><Citation>International Labour Organization. Data 2023 [Cited 01/06/2023]. https://ilostat.ilo.org/data/.</Citation></Reference><Reference><Citation>Jacobsen PA, Andersen MP, Gislason G, Phelps M, Butt JH, Køber L, et al.. Return to work after COVID-19 infection—A Danish nationwide registry study. Public Health. 2022;203:116–22. doi: 10.1016/j.puhe.2021.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2021.12.012</ArticleId><ArticleId IdType="pmc">PMC8786635</ArticleId><ArticleId IdType="pubmed">35038630</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, et al.. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. The Lancet Respiratory Medicine. 2022;10(9):863–76. doi: 10.1016/S2213-2600(22)00126-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Aben B, Kok RN, de Wind A. Return-to-work rates and predictors of absence duration after COVID-19 over the course of the pandemic. Scandinavian Journal of Work, Environment &amp; Health. 2023;(3):182–92. doi: 10.5271/sjweh.4077</Citation><ArticleIdList><ArticleId IdType="doi">10.5271/sjweh.4077</ArticleId><ArticleId IdType="pmc">PMC10621901</ArticleId><ArticleId IdType="pubmed">36587298</ArticleId></ArticleIdList></Reference><Reference><Citation>Marella M, Busija L, Islam FMA, Devine A, Fotis K, Baker SM, et al.. Field-testing of the rapid assessment of disability questionnaire. BMC Public Health. 2014;14(1):900. doi: 10.1186/1471-2458-14-900</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-14-900</ArticleId><ArticleId IdType="pmc">PMC4246465</ArticleId><ArticleId IdType="pubmed">25179800</ArticleId></ArticleIdList></Reference><Reference><Citation>Catharina YP, Kathryn EL, Yunita W, Aaron DS, Amalya M, Angela DI, et al.. Healthcare-seeking behaviors for acute respiratory illness in two communities of Java, Indonesia: a cross-sectional survey. Journal of Epidemiology and Global Health. 2016;6(2):77–86. doi: 10.1016/j.jegh.2016.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jegh.2016.01.002</ArticleId><ArticleId IdType="pmc">PMC5733133</ArticleId><ArticleId IdType="pubmed">26930154</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwi A, Blignault I, Glazebrook D, Correia V, Bateman-Steel C, Ferreira E, et al. Timor-Leste Health Care Seeking Behaviour Study, Final Report 2009.</Citation></Reference><Reference><Citation>Wang Y, Zhao D, Chen X, Liu X, Xiao W, Feng L. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants. Influenza and Other Respiratory Viruses. 2023;17(2):e13095. doi: 10.1111/irv.13095</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13095</ArticleId><ArticleId IdType="pmc">PMC9946694</ArticleId><ArticleId IdType="pubmed">36843224</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator. 2022; [Cited 17/03/2023]. https://www.who.int/news/item/22-04-2022-who-recommends-highly-successful-covid-19-therapy-and-calls-for-wide-geographical-distribution-and-transparency-from-originator</Citation></Reference><Reference><Citation>Medicines Patent Pool. Nirmatrelvir, 2021 [Cited 17/03/2023]. https://medicinespatentpool.org/licence-post/pf-07321332.</Citation></Reference><Reference><Citation>World Health Organization. ACT-Accelerator Outcomes Report, 2020–22. 2022.</Citation></Reference><Reference><Citation>Fu Y, Zhao J, Han P, Zhang J, Wang Q, Wang Q, et al.. Cost-effectiveness of COVID-19 vaccination: A systematic review. Journal of Evidence-Based Medicine. 2023;16(2):152–65. doi: 10.1111/jebm.12525</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jebm.12525</ArticleId><ArticleId IdType="pubmed">37186130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirison K, Nittayasoot N, Techasuwanna R, Cetthakrikul N, Suphanchaimat R. Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance. Tropical Medicine and Infectious Disease. 2023;8(2). doi: 10.3390/tropicalmed8020091</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed8020091</ArticleId><ArticleId IdType="pmc">PMC9959539</ArticleId><ArticleId IdType="pubmed">36828507</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu H, Fairley CK, Zou Z, Xie L, Li X, et al.. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. International Journal of Infectious Diseases. 2022;119:87–94. doi: 10.1016/j.ijid.2022.03.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.03.029</ArticleId><ArticleId IdType="pmc">PMC8938315</ArticleId><ArticleId IdType="pubmed">35338008</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu H, Fairley CK, Ong JJ, Guo Y, Lu P, et al.. mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia. Vaccine. 2023;41(15):2439–46. doi: 10.1016/j.vaccine.2023.01.075</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.01.075</ArticleId><ArticleId IdType="pmc">PMC9894775</ArticleId><ArticleId IdType="pubmed">36781332</ArticleId></ArticleIdList></Reference><Reference><Citation>Savinkina A, Paltiel AD, Ross JS, Gonsalves G. Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis. Open Forum Infectious Diseases. 2022;9(12):ofac637. doi: 10.1093/ofid/ofac637</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac637</ArticleId><ArticleId IdType="pmc">PMC9792084</ArticleId><ArticleId IdType="pubmed">36589482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wai AK-C, Chan CY, Cheung AW-L, Wang K, Chan SC-L, Lee TT-L, et al.. Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. The Lancet Regional Health—Western Pacific. 2023;30. doi: 10.1016/j.lanwpc.2022.100602</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2022.100602</ArticleId><ArticleId IdType="pmc">PMC9532222</ArticleId><ArticleId IdType="pubmed">36212676</ArticleId></ArticleIdList></Reference><Reference><Citation>Edoka I, Drake T, Baker P, Ndembi N, Tajudeen R, Asfaw E, et al.. A cost-effectiveness analysis of Molnupiravir and Paxlovid in three African countries. medRxiv. 2023:2023.07.05.23292205. doi: 10.1101/2023.07.05.23292205</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.07.05.23292205</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, et al.. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925–30. doi: 10.2471/BLT.15.164418</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.15.164418</ArticleId><ArticleId IdType="pmc">PMC5153921</ArticleId><ArticleId IdType="pubmed">27994285</ArticleId></ArticleIdList></Reference><Reference><Citation>Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–24. doi: 10.2471/BLT.14.138206</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.14.138206</ArticleId><ArticleId IdType="pmc">PMC4339959</ArticleId><ArticleId IdType="pubmed">25883405</ArticleId></ArticleIdList></Reference><Reference><Citation>Newall AT, Jit M, Hutubessy R. Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines. PharmacoEconomics. 2014;32(6):525–31. doi: 10.1007/s40273-014-0162-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-014-0162-x</ArticleId><ArticleId IdType="pubmed">24791735</ArticleId></ArticleIdList></Reference><Reference><Citation>Viveiros Rosa S, Rayhan M, Mudatsir M, Nurjannah N, Ichsan I, Amir-Behghadami M, et al.. Acceptance and willingness to purchase a hypothetical COVID-19 vaccine in a region under Shariah law: A cross-sectional study in Aceh, Indonesia. 2022;2:7. doi: 10.52225/narra.v2i2.85</Citation><ArticleIdList><ArticleId IdType="doi">10.52225/narra.v2i2.85</ArticleId><ArticleId IdType="pmc">PMC10914119</ArticleId><ArticleId IdType="pubmed">38449698</ArticleId></ArticleIdList></Reference><Reference><Citation>Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, et al.. Willingness-to-pay for a COVID-19 vaccine and its associated determinants in Indonesia. Human Vaccines &amp; Immunotherapeutics. 2020;16(12):3074–80. doi: 10.1080/21645515.2020.1819741</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1819741</ArticleId><ArticleId IdType="pmc">PMC8641577</ArticleId><ArticleId IdType="pubmed">32991230</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>